Lymphoma Canada is preparing a submission for the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Quebec equivalent Institut national d’excellence en santé et services sociaux (INESSS) for an upcoming drug review on Zanubrutinib, also known as Brukinsa, for relapsed/refractory Mantle Cell lymphoma patients.
If you have Mantle Cell Lymphoma and have received Zanubrutinib, you can help by completing our survey. You can also participate in this survey if you have not received this therapy, and can share your experience about your lymphoma and its impacts on your quality of life.
The survey provides us with the patient input required for the submission. CADTH and INESSS use this information to help make recommendations to the provinces and territories regarding funding for new cancer drugs.
You do not need to live in Canada to complete this survey.
The survey will be open until midnight Pacific Time on Wednesday, October 20th, 2021, and should only take between 15-20 minutes of your time.Survey Closed
Follow us on Social Media to stay up to date and informed on all things Lymphoma Canada!